Ubiquinol
Ubiquinol has been studied in 12 papers since 2012: 7 trials and 1 observational study in people, 2 in animals, 1 review; 4 in the past year. Its furthest trials in people are at phase 3. The newest paper, Sep 2, 2026: “Mitochondria-Targeted Nutraceuticals as Metabolic Adjuncts to Physical Rehabilitation in Older Adults with Sarcopenia or Frailty: A Narrative Review”.
See all 51 papers on ubiquinol
At a glance
The findings reach people, from one lab or study. 5 independent labs in 5 countries; 15 trials, 2 about aging, 3 with no results posted.
“90 days of ubiquinol (200 mg) supplementation resulted in plasma CoQ10 levels being four times that of the placebo group at study end (p < 0.001)”
1 of its findings points the other way.
- 5 independent labs in 5 countries
- 1 finding against
- 15 trials, 2 about aging, 3 with no results posted
- Funders: Australian Government and 6 more
- 2 of 15 trials sponsored by its developers
- Human trial7
- Humans1
- Animals2
Studies in people
See all 6 studies of ubiquinol in people6 studies gave ubiquinol to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Increases plasma CoQ10four times the placebo group no change: Has no effect on cognitive function no change: Has no effect on oxidative stress biomarkers | Randomized trial90 days | 111 people60 years and olderOlder adults; at study end versus placebo | Antioxidants (Basel, Switzerland), Jun 27, 2026 |
no change: Has no effect on oxidized LDL | Randomized trial12 weeks | 20 people18–60 yearsThai adults with prediabetes | BioMed research international, Mar 8, 2026 |
up: Improves flow-mediated dilation+1.28% ± 0.90% (200 mg/day), +1.34% ± 1.44% (100 mg/day) vs −0.41% ± 1.51% (placebo) | Randomized trial8 weeks | 51 peopleaged 35–65 yearsMen and post-menopausal women aged 35–65 years | Nutrients, Apr 15, 2020 |
no change: Has no effect on physical function down: Prevents coenzyme Q10 down: Decreases reactive oxygen species–37.4% and –35.5% | Randomized trial1 month | 21 peoplemales26 ± 5Healthy trained males | Redox report : communications in free radical research, Dec 1, 2018 |
down: Decreases alanine aminotransferase down: Decreases alkaline phosphatase | Randomized trial12 weeks | With simvastatin | Experimental biology and medicine (Maywood, N.J.), Sep 30, 2015 |
What did studies of ubiquinol find?
19Studies of ubiquinol measured 19 outcomes, among them oxidized LDL, oxidative stress and ROS signaling and flow-mediated dilation.
Oxidized LDL
no changein humans1downin humans1downin reviews1
1 study
Oxidized LDL
no changein humans1downin humans1downin reviews1
Ubiquinol showed no clear effect on oxidized LDL in humans.
“At 12 weeks, the between‐group difference in oxLDL was not significant (p = 0.801).”
Human trial12 weeksn = 20
BioMed research international
Ubiquinol decreases oxidized LDL in prediabetic patients (p = 0.049).
“the ubiquinol group demonstrated a significant within-group reduction in plasma oxLDL compared with baseline (p = 0.049)”
Human trialin prediabetic patientsplasma100 mg/day12 weeks
BioMed research international
Ubiquinol decreases oxidized LDL.
“However, the ubiquinol group exhibited a statistically significant within‐group reduction in mean oxLDL from 53.16 ± 6.79 at baseline to 50.16 ± 8.77 after 12 weeks of daily ubiquinol supplement (p = 0.049).”
Review12 weeksn = 10
BioMed research international
Oxidative stress and ROS signaling
downin humans1
1 study
Oxidative stress and ROS signaling
downin humans1
Ubiquinol decreases oxidative stress and ROS signaling in humans.
“A highly significant and dose-dependent decrease in the percentage of oxidized CoQ10 was observed both at 4 weeks (F = 11.023, p < 0.001) and at 8 weeks (F = 10.087; p < 0.001”
Human trial8 weeksn = 51
Nutrients
Ubiquinol decreases oxidative stress and ROS signaling in humans (moderate dyslipidemia) (p = 0.017).
“while LDL oxidation lag time improved significantly in those receiving 200 mg/day (p = 0.017)”
Human trialmoderate dyslipidemiaplasma200 mg/day8 weeksn = 48
Nutrients
Flow-mediated dilation
upin humans1
1 study
Flow-mediated dilation
upin humans1
Ubiquinol improves flow-mediated dilation in humans (+1.28% ± 0.90% (200 mg/day), +1.34% ± 1.44% (100 mg/day) vs −0.41% ± 1.51% (placebo)).
“According to repeated measures one-way ANOVA, at the end of the study (week 8), subjects in both treatment groups showed a significant FMD increase compared with those receiving the placebo (200 mg/day, +1.28% ± 0.90%; 100 mg/day, +1.34% ± 1.44%; placebo −0.41% ± 1.51%; F = 9.145; p < 0.001; ).”
Human trial8 weeksn = 51
Nutrients
Ubiquinol improves flow-mediated dilation in humans (moderate dyslipidemia) (200 mg/day, +1.28% ± 0.90%; 100 mg/day, +1.34% ± 1.44%; p < 0.001).
“demonstrated a significantly increased FMD in both treated groups compared with the placebo group (200 mg/day, +1.28% ± 0.90%; 100 mg/day, +1.34% ± 1.44%; p < 0.001)”
Human trialmoderate dyslipidemiabrachial artery100 or 200 mg/day8 weeksn = 48
Nutrients
Reactive oxygen species
downin humans1
1 study
Reactive oxygen species
downin humans1
Ubiquinol decreases reactive oxygen species in humans (–37.4% and –35.5%).
“However, in the recovery phase, a distinct ROS scavenging effect was evident: a highly significant decrease in intracellular ROS was observed in the ubiquinol treated group at 90 and 150 min (–37.4% and –35.5%; p <.01).”
Human trialPBMCs1 monthmalesn = 21
Redox report : communications in free radical research
Ubiquinol decreases reactive oxygen species in humans after a single bout of intense exercise.
“ubiquinol supplementation was associated with a significant decrease in cytosolic ROS”
Human trialafter a single bout of intense exercisesupplementationperipheral blood mononuclear cells200 mg/day1 monthmalesn = 21
Redox report : communications in free radical research
Aspartate aminotransferase
no changein humans1
1 study
Aspartate aminotransferase
no changein humans1
Ubiquinol showed no clear effect on aspartate aminotransferase.
“In contrast, we found no alteration of AST activity in response to Q10H2 supplementation.”
Human trial14 daysmalesn = 53
Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans
BMC research notes
Ubiquinol showed no clear effect on aspartate aminotransferase in humans (cohort II).
“Of note, other liver enzymes (i.e., aspartate aminotransferase, AST) were not affected by Q10H2 supplementation.”
Human trialcohort II150 mg/d14-daymalesn = 53
Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans
BMC research notes
GGT1
downin humans1
1 study
GGT1
downin humans1
Ubiquinol decreases GGT1 (fold change of -1.49).
“Indeed, we found that Q10H2 supplementation reduced the GGT1 mRNA level with a fold change of -1.49 and the GOT2 mRNA level with a fold change of -1.34.”
Human trial14 daysn = 3
Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans
BMC research notes
Ubiquinol decreases GGT1 in humans (cohort II) (1.49-fold).
“GGT1 mRNA levels declined 1.49-fold after Q10H2 supplementation.”
Human trialcohort II150 mg/d14-daymalesn = 53
Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans
BMC research notes
Gamma-glutamyltransferase
downin humans1
1 study
Gamma-glutamyltransferase
downin humans1
Ubiquinol decreases gamma-glutamyltransferase (20.49 ± 10.36 U/l to 17.79 ± 7.68 U/l).
“Figure A shows a significant decrease of GGT activity from T0 to T14 (20.49 ± 10.36 U/l to 17.79 ± 7.68 U/l; p < 0.001).”
Human trial14 daysmalesn = 53
Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans
BMC research notes
Ubiquinol decreases gamma-glutamyltransferase in humans (cohort II) (p < 0.001).
“Q10H2 supplementation (cohort II) caused a significant decrease in serum GGT activity from T0 to T14 (p < 0.001).”
Human trialcohort IIsupplementationserum150 mg/d14-daymalesn = 53
Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans
BMC research notes
Inflammation biomarkers
no changein humans1
1 study
Inflammation biomarkers
no changein humans1
Ubiquinol showed no clear effect on inflammation biomarkers in humans (at study end, adjusted for baseline values and demographics).
“ubiquinol supplementation did not facilitate group differences (controlling for baseline values and relevant demographics) in cognitive function, blood biomarkers reflective of oxidative stress or inflammation”
Human trialat study end, adjusted for baseline values and demographics200 mg90 days
Antioxidants (Basel, Switzerland)
Oxidative stress biomarkers
no changein humans1
1 study
Oxidative stress biomarkers
no changein humans1
Ubiquinol showed no clear effect on oxidative stress biomarkers in humans (at study end, adjusted for baseline values and demographics).
“ubiquinol supplementation did not facilitate group differences (controlling for baseline values and relevant demographics) in cognitive function, blood biomarkers reflective of oxidative stress or inflammation”
Human trialat study end, adjusted for baseline values and demographics200 mg90 days
Antioxidants (Basel, Switzerland)
Cognitive function
no changein humans1
1 study
Cognitive function
no changein humans1
Ubiquinol showed no clear effect on cognitive function in humans (at study end, adjusted for baseline values and demographics).
“ubiquinol supplementation did not facilitate group differences (controlling for baseline values and relevant demographics) in cognitive function, blood biomarkers reflective of oxidative stress or inflammation”
Human trialat study end, adjusted for baseline values and demographics200 mg90 days
Antioxidants (Basel, Switzerland)
Plasma CoQ10
upin humans1
1 study
Plasma CoQ10
upin humans1
Ubiquinol increases plasma CoQ10 in humans (at study end versus placebo) (four times the placebo group).
“90 days of ubiquinol (200 mg) supplementation resulted in plasma CoQ10 levels being four times that of the placebo group at study end (p < 0.001)”
Human trialat study end versus placebo200 mg90 days
Antioxidants (Basel, Switzerland)
Coenzyme Q10
downin humans1
1 study
Coenzyme Q10
downin humans1
Ubiquinol prevents coenzyme Q10 in humans.
“This increase efficiently counteracted CoQ10 deprivation induced by exercise.”
Human trialplasma1 monthmalesn = 21
Redox report : communications in free radical research
Physical function
no changein humans1
1 study
Physical function
no changein humans1
Ubiquinol showed no clear effect on physical function in humans.
“No significant differences were observed in terms of ability of ubiquinol to allow a prolonged run at higher speed.”
Human trial1 monthmalesn = 21
Redox report : communications in free radical research
Alkaline phosphatase
downin humans1
1 study
Alkaline phosphatase
downin humans1
Ubiquinol decreases alkaline phosphatase in humans with simvastatin.
“In ubiquinol supplementation group, alanine aminotransferase and alkaline phosphatase were significantly down-regulated after 12 weeks”
Human trialwith simvastatin12 weeks
Experimental biology and medicine (Maywood, N.J.)
Alanine aminotransferase
downin humans1
1 study
Alanine aminotransferase
downin humans1
Ubiquinol decreases alanine aminotransferase in humans with simvastatin.
“In ubiquinol supplementation group, alanine aminotransferase and alkaline phosphatase were significantly down-regulated after 12 weeks”
Human trialwith simvastatin12 weeks
Experimental biology and medicine (Maywood, N.J.)
All 19Fewer
Has ubiquinol been tested in people?
2 of 15 about agingYes: 7 trials and 1 observational study in people have been published, and 14 trials are registered.
About aging
Every condition in trials
Phase 3Results posted1 trial
Phase 3Results posted1 trial
Phase 3Results posted1 trial
Phase 3Results posted1 trial
Phase 3Results posted1 trial
Phase 3Results posted1 trial
All 19Fewer
Readouts due
- Jan 8, 2027
- Sep 1, 2027
Ubiquinone vs. Ubiquinol Supplementation
Phase 2Recruiting
Trial sponsors
Company1 trial23 people
VA Office of Research and Development
1 trialPhase 3100 people
1 trialPhase 2/3150 people
1 trialPhase 2/3100 people
Beth Israel Deaconess Medical Center
2 trialsPhase 286 people
1 trialPhase 290 people
1 trialPhase 240 people
1 trialPhase 16 people